Entrust Financial’s Akebia Therapeutics AKBA Stock Holding History

Entrust Financial’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$827	Buy	+725	New	+$863	﹤0.01%	431

Other funds holding AKBA

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

Wealth Enhancement Advisory Services

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Independent Wealth Network Urbandale, Iowa $393M AUM 30.08% 1-Year Est. Return

Eagle Wealth Strategies West Deptford, New Jersey $262M AUM 31.52% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Entrust Financial's AKBA Position: Q2 2026 in Review

Entrust Financial opened a new position in Akebia Therapeutics (AKBA) in Q2 2026: 725 shares worth $827. The stake represents ﹤0.01% of the portfolio and ranks #431 among its holdings.

13 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

Entrust Financial held 725 shares of Akebia Therapeutics worth $827 as of Q2 2026.
Akebia Therapeutics was a new Entrust Financial position in Q2 2026.
Akebia Therapeutics made up ﹤0.01% of Entrust Financial's portfolio in Q2 2026, its #431 holding.
13 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Entrust Financial's 13F filing for Q2 2026, filed 20 Jul 2026.